INO-5401
Cancer Prevention in BRCA1/2 Mutation Carriers
Phase 1Not Recruiting
Key Facts
Indication
Cancer Prevention in BRCA1/2 Mutation Carriers
Phase
Phase 1
Status
Not Recruiting
Company
About Inovio Pharmaceuticals
Inovio Pharmaceuticals is a trailblazer in the DNA medicine field, leveraging its SynCon® and CELLECTRA® platform to develop next-generation immunotherapies. The company has a diverse clinical pipeline targeting HPV-related conditions, cancer, and infectious diseases, with a significant milestone being the FDA's acceptance of its first Biologics License Application (BLA) for INO-3107 in RRP. With a strong history of collaboration with government, academic, and industry partners, Inovio is strategically positioned to advance its platform and bring novel, potentially transformative treatments to market.
View full company profile